United States Patent 8,901,349: Claim Scope, Validity Risks, and Ferric Citrate Patent Landscape

U.S. Patent No. 8,901,349 protects the use of high-surface-area ferric citrate in oral dosage forms to treat hyperphosphatemia. Its core limitation is not ferric citrate alone. The claims require ferric citrate with a BET active surface area greater than about 16 m²/g, with narrower claims directed to intrinsic dissolution rate, dosage, chemical identity, dosage form, and human treatment.

The patent is a method-of-treatment patent, not a conventional composition-of-matter patent. Its commercial significance depends on whether a competing ferric citrate product uses API meeting the claimed surface-area and dissolution parameters and is marketed for hyperphosphatemia.

What does U.S. Patent 8,901,349 cover?

The patent covers administering an oral ferric citrate product made from ferric citrate having a BET active surface area above approximately 16 m²/g to treat hyperphosphatemia.

Feature	Claim requirement
Therapeutic use	Treatment of hyperphosphatemia
Active ingredient	Ferric citrate
Physical property	BET active surface area greater than about 16 m²/g
Administration	Oral
Dosage-form scope	Tablet, powder, capsule, granule, troche, or pill
Optional dissolution limitation	Intrinsic dissolution rate of at least 1.88 mg/cm²/min
Chemical formula	C6H5O7Fe
Dosage limitation	About 3 to 6 grams per day
Patient limitation	Human being under claim 9

The claim set is structured around a physical-property distinction. A product containing ferric citrate may fall outside the claims if the relevant ferric citrate material has a BET active surface area at or below the claimed threshold, provided the manufacturer can establish that result using a defensible analytical method.

How do the individual claims operate?

Claim 1: Core method claim

Claim 1 requires all of the following:

Treatment of hyperphosphatemia.
Administration of a therapeutically effective amount.
An orally administrable ferric citrate form.
Preparation from ferric citrate having a BET active surface area greater than about 16 m²/g.
A listed dosage form: tablet, powder, capsule, granule, troche, or pill.

The claim does not expressly require:

Chronic kidney disease.
Dialysis.
A particular serum phosphate level.
A particular patient population.
A specific excipient.
A specific tablet strength.
A particular ferric-to-citrate ratio beyond ferric citrate itself.
A specified dosing schedule.
The 3-to-6 gram daily dose appearing in claim 8.

The claim therefore reaches beyond the approved Auryxia population if the other limitations are met. A non-dialysis patient, a dialysis patient, or another human with hyperphosphatemia could fall within the claim.

The phrase "prepared from a form of ferric citrate" is important. The claim is directed to the source ferric citrate material used to make the oral dosage form. It does not clearly require that the finished tablet retain an independently measurable BET surface area above 16 m²/g after compression and formulation.

Claim 2: BET range from approximately 16 to 20 m²/g

Claim 2 narrows claim 1 to a BET active surface area ranging from about 16 to about 20 m²/g.

The claims overlap at the boundary because claim 1 requires a value greater than about 16 m²/g, while claim 2 uses "about 16." The term "about" creates a potential claim-construction issue concerning analytical variability and the acceptable deviation from the numerical endpoints.

A competing product with a reported BET value of 16.1 m²/g could be materially different from one measuring 19.8 m²/g, but both could implicate claim 2 depending on the patent's specification, test protocol, and accepted measurement tolerance.

Claims 3 through 5: Intrinsic dissolution rate

Claim 3 adds an intrinsic dissolution rate of at least 1.88 mg/cm²/min.

Claim 4 narrows the rate to 1.88 to 4.0 mg/cm²/min. Claim 5 uses a slightly narrower lower bound of 1.9 mg/cm²/min and the same 4.0 mg/cm²/min upper bound.

Claim	Intrinsic dissolution rate
Claim 3	At least 1.88 mg/cm²/min
Claim 4	1.88 to 4.0 mg/cm²/min
Claim 5	1.9 to 4.0 mg/cm²/min

Claims 4 and 5 are not redundant. Claim 5 excludes the interval from 1.88 to below 1.9 mg/cm²/min, subject to the treatment of rounding and "about" language elsewhere in the patent.

Intrinsic dissolution rate is a testing-sensitive limitation. Litigation would likely focus on:

Medium composition and pH.
Temperature.
Apparatus and agitation.
Exposed surface area.
Sample compaction.
Test duration.
Calculation method.
Whether the result is measured on ferric citrate API or the finished dosage form.

A generic applicant could seek non-infringement by demonstrating that its ferric citrate material satisfies the BET limitation but falls below the intrinsic dissolution threshold, or vice versa. That strategy would not avoid claim 1 if the BET limitation remains satisfied.

Claim 6: Chemical identity

Claim 6 specifies ferric citrate having the formula C6H5O7Fe.

This limitation attempts to identify the active compound more precisely, but it does not convert the patent into a broad composition patent. Claim 6 remains dependent on the treatment, oral dosage-form, and BET limitations inherited from claim 1.

The formula may also create an analytical issue because ferric citrate can exist in hydrated, amorphous, complexed, or variable stoichiometric forms. The legal question is whether the accused material is properly characterized as ferric citrate within the patent's disclosure and accepted pharmaceutical usage.

Claim 7: Tablet

Claim 7 narrows the dosage form to a tablet. This is commercially significant because Auryxia is marketed as an oral tablet. The claim does not require a particular tablet weight, coating, imprint, excipient system, or strength.

A competing ferric citrate tablet would face a direct infringement risk if:

It is marketed for hyperphosphatemia.
It is made using ferric citrate with the claimed BET surface area.
The tablet is administered in the United States.
The product satisfies the remaining limitations.

Claim 8: Daily dose of approximately 3 to 6 grams

Claim 8 covers a therapeutically effective amount of about 3 to 6 grams per day. The claim does not state whether the measurement refers to ferric citrate mass, elemental iron mass, or another dosing convention. That issue would require interpretation from the specification and prosecution history.

The limitation may be commercially relevant because ferric citrate phosphate binders are administered in gram quantities. A label recommending a daily dose within the claimed range could support inducement allegations if the underlying API and other limitations are present.

Claim 9: Human treatment

Claim 9 limits claim 1 to treatment of a human being. This claim is narrower than claim 1 if claim 1 is interpreted to cover non-human subjects. It aligns the claim with the human therapeutic market and may be easier to enforce against a human pharmaceutical product than against veterinary applications.

What is the patent's likely legal term?

The patent family is associated with an earliest priority date in December 2006. On a standard U.S. patent-term calculation, the nominal expiration date is approximately December 2027, subject to terminal disclaimers, patent-term adjustment, patent-term extension, and any applicable statutory changes.

Event	Approximate date
Earliest priority	December 2006
U.S. patent issuance	December 2, 2014
Standard 20-year term endpoint	December 2027
Patent status before term endpoint	Dependent on maintenance, disclaimer, and term adjustments

The issuance date does not control expiration for a post-June 8, 1995 U.S. patent. The relevant calculation generally runs from the earliest effective nonprovisional or international filing date, not from issuance. Patent-term adjustment can extend the date, while a terminal disclaimer can limit it.

What patents protect Auryxia and ferric citrate products?

U.S. Patent 8,901,349 is one part of the broader ferric citrate patent estate associated with Auryxia. The estate has included several patent families directed to different aspects of the product, including:

Ferric citrate compositions.
Physical properties and particle characteristics.
Oral formulations.
Methods of treating hyperphosphatemia.
Methods of treating iron deficiency anemia in chronic kidney disease.
Manufacturing and product specifications.
Additional method-of-use and formulation claims.

The key distinction is between patents that claim the active material itself and patents that claim use of the material. A composition patent may create a broader barrier to substitution, while a method patent can be avoided by a non-infringing label or by using API outside the claimed physical-property range.

How strong is the patent estate for ferric citrate?

The estate is commercially stronger when multiple claim categories overlap:

Patent category	Protection against generic entry
Composition claims	Broadest potential product coverage
High-BET API claims	Targets API sourcing and manufacturing
Formulation claims	Targets finished tablets and dosage forms
Method-of-use claims	Targets labeled hyperphosphatemia treatment
Dissolution claims	Adds analytical and performance limitations
Manufacturing claims	Can complicate independent API production

U.S. Patent 8,901,349 is strongest against a generic that copies the physical-property profile of the branded product and uses a hyperphosphatemia indication. It is weaker against a product that uses a materially different ferric citrate form, does not satisfy the BET threshold, or uses a label that omits the patented indication where legally and commercially feasible.

What is the FDA regulatory status of ferric citrate?

The FDA approved Auryxia, ferric citrate tablets, under NDA 205874 in 2014 for control of serum phosphorus levels in adults with chronic kidney disease on dialysis. The FDA later approved an expanded indication for treatment of iron deficiency anemia in adults with chronic kidney disease not on dialysis. [2]

The FDA-approved product is a tablet. That fact makes claim 7 particularly relevant, although FDA approval alone does not establish infringement. Infringement depends on the product's actual composition, manufacturing specifications, physical properties, labeling, and use.

Ferric citrate is a small-molecule drug. Biosimilar law does not apply. The relevant competitive pathway is an abbreviated new drug application under section 505(j) of the Federal Food, Drug, and Cosmetic Act, not a biosimilar application under the Public Health Service Act. [3]

What is the Orange Book status of U.S. Patent 8,901,349?

Orange Book listing is product-specific. A patent must be listed against the relevant NDA and must claim the drug substance, drug product, or an approved method of use under FDA listing rules. [4]

A patent may be relevant to Auryxia without being the only patent listed for the product. The practical questions are:

Whether U.S. Patent 8,901,349 is listed against the approved NDA.
Which claims are identified as covering the approved method of use.
The expiration date shown in the current Orange Book.
Whether pediatric exclusivity or patent-term adjustment modifies the listed date.
Whether an ANDA applicant submitted a Paragraph IV certification to the patent.

Because Orange Book status changes through FDA listing updates, the current FDA publication controls over older litigation summaries or commercial databases. The patent’s independent claim structure indicates that, if listed, it would most naturally be treated as a method-of-use patent rather than a drug-substance patent.

Which companies are challenging ferric citrate exclusivity?

Generic competition to Auryxia is assessed through ANDA filings and Paragraph IV certifications. A Paragraph IV certification asserts that a listed patent is invalid, unenforceable, or not infringed. Filing an ANDA with a Paragraph IV certification can trigger litigation under 21 U.S.C. § 355(j)(5)(B)(iii). [3]

The relevant challenger categories are:

Generic companies filing ANDAs for ferric citrate tablets.
Contract manufacturers supplying ferric citrate API.
Applicants pursuing labels that include hyperphosphatemia treatment.
Applicants using alternative physical-property specifications.

A Paragraph IV challenge to a composition or formulation patent may present a different risk profile from a challenge to U.S. Patent 8,901,349. A successful non-infringement position against the BET limitation would not necessarily avoid separately listed composition, formulation, or method-of-use patents.

Public litigation records should be analyzed patent by patent. A settlement involving one listed patent does not necessarily resolve the entire Auryxia patent estate.

What infringement issues are most important?

BET measurement

The central technical issue is whether the accused ferric citrate has a BET active surface area greater than about 16 m²/g. The result may vary with:

Degassing conditions.
Adsorption gas.
Instrument calibration.
Sample preparation.
Moisture content.
Particle aggregation.
Lot-to-lot variability.

A manufacturer seeking to design around the claim would need consistent batch specifications, not a single favorable test result.

Intrinsic dissolution testing

Claims 3 through 5 create additional but narrower enforcement positions. A product may meet the BET threshold while failing the dissolution limitation. Conversely, a product may show high dissolution but fall outside the claimed BET range.

Label-induced infringement

A generic label directing use for hyperphosphatemia could support an induced-infringement theory if the product meets the claimed physical properties and the manufacturer knows of the patent. A label limited to an unclaimed indication may reduce risk, but the commercial feasibility of a carve-out depends on the approved labeling, prescribing practices, and the scope of other patents.

Dosage-form coverage

The listed dosage forms make the claims broader than a tablet-only claim. Powder, capsule, granule, troche, and pill products can be covered. A liquid product may fall outside the literal dosage-form list, although other claims or patent families could still apply.

How does this patent compare with a composition patent?

Issue	U.S. Patent 8,901,349	Composition patent
Primary subject	Treatment method using high-BET ferric citrate	Ferric citrate or a defined composition
Key proof	Patient use, label, dosage form, BET property	Product identity and composition
Design-around potential	Higher	Usually lower
Relevance to generic label	High	Moderate to high
Dependence on analytical testing	High	Variable
Scope over off-label use	Potentially significant	Usually product-focused
Biosimilar relevance	None	None

U.S. Patent 8,901,349 does not by itself prevent all ferric citrate products. It targets a defined therapeutic use of a defined physical form of ferric citrate.

What generic launch scenarios exist?

Scenario 1: Launch after patent expiration

A generic launches after the relevant listed patents expire and any applicable exclusivity ends. This is the lowest litigation-risk scenario.

Scenario 2: Paragraph IV litigation settlement

The applicant resolves litigation through a settlement containing an agreed launch date, manufacturing restrictions, or other terms. The commercial result depends on the full patent estate, not only U.S. Patent 8,901,349.

Scenario 3: Non-infringing high-purity or low-BET product

The applicant develops ferric citrate that does not meet the BET threshold. This requires validated specifications and may create separate regulatory comparability questions.

Scenario 4: Carved-out labeling

The applicant omits a patented indication or use from its label. This may reduce induced-infringement exposure but does not eliminate risk from physician use, other patents, or product claims.

Scenario 5: At-risk launch

The applicant launches before final resolution of patent litigation. Exposure can include damages, injunctive relief, and potential launch disruption.

What is the geographic coverage?

U.S. Patent 8,901,349 applies only in the United States. Foreign counterpart patents require separate review in each jurisdiction. The commercial impact differs by country because:

Patent-term rules vary.
Patent claims may have been amended during national-phase prosecution.
Method-of-treatment claims may face different eligibility rules.
Regulatory exclusivity periods differ.
Orange Book-style listing systems are not uniform.
Generic approval pathways vary.

A U.S. freedom-to-operate conclusion cannot be extended to Europe, Japan, Canada, China, or other markets without reviewing the relevant national patent families.

Key Takeaways

U.S. Patent 8,901,349 is a method-of-treatment patent covering oral ferric citrate for hyperphosphatemia.
Its defining limitation is ferric citrate with a BET active surface area greater than about 16 m²/g.
Claims 3 through 5 add intrinsic dissolution-rate requirements ranging from at least 1.88 mg/cm²/min to 4.0 mg/cm²/min.
Claims 7 and 8 are commercially aligned with tablet administration and a 3-to-6 gram daily dose.
Claim 9 limits the method to human treatment.
The patent does not claim ferric citrate without the physical-property and therapeutic-use limitations.
It is relevant to Auryxia because Auryxia is an oral ferric citrate tablet approved for hyperphosphatemia in adults with chronic kidney disease on dialysis.
Generic risk depends on the accused product’s BET value, dissolution rate, dosage form, label, and overlap with other Auryxia patents.
Ferric citrate is a small molecule. Biosimilar risk is not applicable.
The nominal patent term is approximately through December 2027, subject to the official patent-term calculation and Orange Book record.

FAQs

Does U.S. Patent 8,901,349 cover every ferric citrate product?

No. The claims require a therapeutic use for hyperphosphatemia and ferric citrate with the specified BET surface-area limitation. Products outside those limitations may avoid this patent, although other patents may apply.

Can a generic avoid the patent by using a different tablet formulation?

Possibly, but changing excipients or tablet design may not avoid infringement if the product is still made from ferric citrate with a BET surface area above about 16 m²/g and is labeled for hyperphosphatemia.

Is a ferric citrate liquid covered by the claims?

The listed dosage forms are tablet, powder, capsule, granule, troche, and pill. A liquid is not expressly listed in claim 1, but other claims or related patents could cover a liquid product.

Does a Paragraph IV challenge automatically invalidate the patent?

No. A Paragraph IV certification is an applicant’s legal position that the patent is invalid, unenforceable, or not infringed. The position can be resolved through litigation, settlement, or regulatory procedures.

Are ferric citrate products subject to biosimilar competition?

No. Ferric citrate is a small-molecule drug. Competition proceeds through generic-drug pathways, principally ANDAs, rather than biosimilar applications.

References

United States Patent No. 8,901,349. (2014). Methods of treating hyperphosphatemia. U.S. Patent and Trademark Office.
U.S. Food and Drug Administration. (2014). Auryxia (ferric citrate) tablets: Prescribing information.
Federal Food, Drug, and Cosmetic Act, 21 U.S.C. § 355(j).
U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations: Orange Book.
U.S. Patent and Trademark Office. (2024). Manual of patent examining procedure, patent term and patent-term adjustment provisions.

Country	Patent Number	Estimated Expiration	Supplementary Protection Certificate	SPC Country	SPC Expiration
Australia	2004213819	⤷ Start Trial
Australia	2006279333	⤷ Start Trial
Australia	2007210090	⤷ Start Trial
Australia	2007210096	⤷ Start Trial
Canada	2516471	⤷ Start Trial
Canada	2619591	⤷ Start Trial
Canada	2640763	⤷ Start Trial
>Country	>Patent Number	>Estimated Expiration	>Supplementary Protection Certificate	>SPC Country	>SPC Expiration

Summary for Patent: 8,901,349